Pacira BioSciences Inc. (PCRX)
Pacira BioSciences Statistics
Share Statistics
Pacira BioSciences has 46.28M shares outstanding. The number of shares has increased by -0.58% in one year.
| Shares Outstanding | 46.28M |
| Shares Change (YoY) | -0.58% |
| Shares Change (QoQ) | 0.22% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 43.49M |
| Failed to Deliver (FTD) Shares | 228 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 5.93M, so 12.82% of the outstanding shares have been sold short.
| Short Interest | 5.93M |
| Short % of Shares Out | 12.82% |
| Short % of Float | 18.65% |
| Short Ratio (days to cover) | 6.08 |
Valuation Ratios
The PE ratio is -8.75 and the forward PE ratio is 6.62. Pacira BioSciences's PEG ratio is 0.03.
| PE Ratio | -8.75 |
| Forward PE | 6.62 |
| PS Ratio | 1.24 |
| Forward PS | 1.1 |
| PB Ratio | 1.12 |
| P/FCF Ratio | 4.87 |
| PEG Ratio | 0.03 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Pacira BioSciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.4, with a Debt / Equity ratio of 0.63.
| Current Ratio | 2.4 |
| Quick Ratio | 2 |
| Debt / Equity | 0.63 |
| Debt / EBITDA | 16.83 |
| Debt / FCF | 2.74 |
| Interest Coverage | -5.46 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $889.55K |
| Profits Per Employee | $-126.35K |
| Employee Count | 788 |
| Asset Turnover | 0.45 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 36.45M |
| Effective Tax Rate | -57.77% |
Stock Price Statistics
The stock price has increased by -5.59% in the last 52 weeks. The beta is 0.71, so Pacira BioSciences's price volatility has been higher than the market average.
| Beta | 0.71 |
| 52-Week Price Change | -5.59% |
| 50-Day Moving Average | 24.62 |
| 200-Day Moving Average | 19.72 |
| Relative Strength Index (RSI) | 51.22 |
| Average Volume (20 Days) | 935.56K |
Income Statement
In the last 12 months, Pacira BioSciences had revenue of 700.97M and earned -99.56M in profits. Earnings per share was -2.15.
| Revenue | 700.97M |
| Gross Profit | 700.97M |
| Operating Income | -73.37M |
| Net Income | -99.56M |
| EBITDA | 29.12M |
| EBIT | -49.67M |
| Earnings Per Share (EPS) | -2.15 |
Balance Sheet
The company has 276.77M in cash and 490M in debt, giving a net cash position of -213.22M.
| Cash & Cash Equivalents | 276.77M |
| Total Debt | 490M |
| Net Cash | -213.22M |
| Retained Earnings | -206.36M |
| Total Assets | 1.55B |
| Working Capital | 435.21M |
Cash Flow
In the last 12 months, operating cash flow was 189.39M and capital expenditures -10.64M, giving a free cash flow of 178.75M.
| Operating Cash Flow | 189.39M |
| Capital Expenditures | -10.64M |
| Free Cash Flow | 178.75M |
| FCF Per Share | 3.87 |
Margins
Gross margin is 100%, with operating and profit margins of -10.47% and -14.2%.
| Gross Margin | 100% |
| Operating Margin | -10.47% |
| Pretax Margin | -9% |
| Profit Margin | -14.2% |
| EBITDA Margin | 4.15% |
| EBIT Margin | -10.47% |
| FCF Margin | 25.5% |
Dividends & Yields
PCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for PCRX is $25, which is 1.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $25 |
| Price Target Difference | 1.5% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Scores
| Altman Z-Score | 1.37 |
| Piotroski F-Score | 6 |